Exenatide — Discount Pricing

Other medications in Diabetes & Metabolism

• Finerenone
• Glimepiride
• Glipizide
• Glyburide
• Insulin Aspart
• Insulin Degludec
• Insulin Detemir
• Insulin Glargine

What Exenatide is approved for (FDA label)

Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.

Source: Read the full FDA label on DailyMed. Label effective date: May 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Exenatide (FDA label)

Exenatide Injection, USP is a clear, colorless sterile solution for subcutaneous injection containing 250 mcg/mL exenatide, USP supplied as follows: 5 mcg per dose in a single-patient-use prefilled pen containing 300 mcg/1.2 mL (250mcg/mL), 60 doses. 10 mcg per dose in a single-patient-use prefilled pen containing 600 mcg/2.4 mL (250mcg/mL), 60 doses. Exenatide injection is supplied as: 5 mcg per dose, in a single-patient-use prefilled pen containing 300 mcg/1.2 mL (250 mcg/mL), 60 doses. 10 mcg per dose, in a single-patient-use prefilled pen containing 600 mcg/2.4 mL (250 mcg/mL), 60 doses.

Source: FDA prescribing information (DailyMed). Set ID: e6cb5c8f-e97f-4a6a-95a4-939fd2393949. SPL document ID: 2141c3ca-074a-4098-85da-1ef78ec4d4dc. Label effective date: May 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Exenatide (FDA label)

The following serious adverse reactions are described below or elsewhere in the prescribing information: Acute Pancreatitis [see Warnings and Precautions (5.1) ] Never Share an Exenatide Pen Between Patients [see Warnings and Precautions (5.2) ] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ] Immunogenicity [see Warnings and Precautions (5.6) ] Hypersensitivity [see Warnings and Precautions (5.7) ] Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ] Acute Gallbladder Disease [see Warnings and Precautions (5.9) ] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.10) ] Most common (≥ 5%) and occurring more frequently than placebo in clinical trials: nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia.

Source: FDA prescribing information (DailyMed). Set ID: e6cb5c8f-e97f-4a6a-95a4-939fd2393949. SPL document ID: 2141c3ca-074a-4098-85da-1ef78ec4d4dc. Label effective date: May 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Exenatide (FDA label)

Exenatide injection is contraindicated in patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection [see Warnings and Precautions (5.7) ] . A history of drug-induced immune-mediated thrombocytopenia from exenatide products. Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions (5.8) ]. History of severe hypersensitivity to exenatide or any of the excipients in exenatide injection. ( 4 ) History of drug-induced immune-mediated thrombocytopenia from exenatide products. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: e6cb5c8f-e97f-4a6a-95a4-939fd2393949. SPL document ID: 2141c3ca-074a-4098-85da-1ef78ec4d4dc. Label effective date: May 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Exenatide (FDA label)

Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including exenatide. Discontinue if pancreatitis is suspected. ( 5.1 ) Never share an exenatide injection pen between patients, even if the needle is changed. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may be necessary. ( 5.3 ) Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.4 ) Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. Exenatide is not recommended in patients with severe gastroparesis. ( 5.5 ) Immunogenicity : Patients may develop antibodies to exenatide.

Source: FDA prescribing information (DailyMed). Set ID: e6cb5c8f-e97f-4a6a-95a4-939fd2393949. SPL document ID: 2141c3ca-074a-4098-85da-1ef78ec4d4dc. Label effective date: May 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Exenatide (FDA label)

Table 6: Clinically Relevant Interactions with Exenatide Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . Intervention When initiating exenatide, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia. Warfarin Clinical Impact In a drug interaction study, exenatide did not have a significant effect on INR [see Clinical Pharmacology (12.3) ] . There have been post-marketing reports for exenatide of increased INR with concomitant use of warfarin, sometimes associated with bleeding [see Adverse Reactions (6.2) ] . Intervention In patients taking warfarin, the prothrombin time should be monitored more frequently after initiation or alteration of exenatide therapy.

Source: FDA prescribing information (DailyMed). Set ID: e6cb5c8f-e97f-4a6a-95a4-939fd2393949. SPL document ID: 2141c3ca-074a-4098-85da-1ef78ec4d4dc. Label effective date: May 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.